首页> 外文OA文献 >A Phase I Study of Gemtuzumab Ozogamicin in Combination With a Myeloablative Conditioning (MAC) Regimen and alloSCT in Children With High-Risk CD33+ AML: A New Targeted Immunochemotherapy Conditioning Regimen (GO-BU/CY)

【2h】

A Phase I Study of Gemtuzumab Ozogamicin in Combination With a Myeloablative Conditioning (MAC) Regimen and alloSCT in Children With High-Risk CD33+ AML: A New Targeted Immunochemotherapy Conditioning Regimen (GO-BU/CY)

机译：高危CD33 + AML患儿吉莫单抗奥佐加汀与清髓调理（MAC）方案和alloSCT联合进行的I期研究：一种新型靶向免疫化学疗法调理方案（GO-BU / CY）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Satwani P.; Dela Cruz F.; Le Gall J.; Jin Z.; Bhatia M.; Garvin J.H.; George D.; Schwartz J.; van de Ven C.; Morris E.; Baxter-Lowe L.A.; Cairo M.S.;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. A Phase I Study of Gemtuzumab Ozogamicin (GO) in Combination with Busulfan and Cyclophosphamide (Bu/Cy) and Allogeneic Stem Cell Transplantation in Children with Poor-Risk CD33 + AML: A New Targeted Immunochemotherapy Myeloablative Conditioning (MAC) Regimen [J] . SatwaniP., BhatiaM., GarvinJ.H., Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2012,第2期

机译：CD33 + AML不良儿童患儿吉莫单抗唑佐米星（GO）与环丁硫唑和环磷酰胺（Bu / Cy）联合同种异体干细胞移植的I期研究：一种新的靶向免疫化学疗法清髓疗法（MAC）方案
2. REDUCED INTENSITY CONDITIONING AND ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOSCT) FOLLOWED BY TARGETED CONSOLIDATION IMMUNOTHERAPY WITH GEMTUZUMAB OZOGAMICIN (GO) IN CHILDREN AND ADOLESCENTS WITH CD33+ACUTE MYELOID LEUKEMIA (AML) [J] . Zahler Stacey Pediatric blood & cancer . 2015,第Suppla2期

机译：有针对性的巩固治疗与吉美他珠单抗（GO）在儿童和青少年中CD33 +急性髓性白血病（AML）的靶向巩固免疫治疗后，降低了强度和进行了同种干细胞移植（同种异体干细胞）
3. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. [J] . Tsimberidou A, Cortes J, Thomas D, Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis . 2003,第10期

机译：CD33 +原发性耐药或复发的急性髓细胞性白血病患者中的吉姆单抗ozogamicin，氟达拉滨，阿糖胞苷和环孢素联合治疗方案。
4. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013) [O] . Theo de Witte, Stefan Suciu, Liv Meert, -1

机译：依达比星和阿糖胞苷联合吉妥珠单抗奥佐米星（IAGO）用于治疗未经治疗的MDS或高危MDS或AML的患者：EORTC和GIMEMA白血病小组的II期研究（协议06013）
5. A Phase I Study of Gemtuzumab Ozogamicin (GO) in Combination with Busulfan and Cyclophosphamide (Bu/Cy) and Allogeneic Stem Cell Transplantation in Children with Poor-Risk CD33+ AML: A New Targeted Immunochemotherapy Myeloablative Conditioning (MAC) Regimen [O] . Satwani Prakash, Bhatia Monica, Garvin James H., 2012

机译：Gemtuzumab唑佐米星（GO）与白消安和环磷酰胺（Bu / Cy）联合应用和同种异体干细胞移植治疗低危CD33 + AML儿童的I期研究：一种新的靶向免疫化学疗法清髓调理（MAC）方案

A Phase I Study of Gemtuzumab Ozogamicin in Combination With a Myeloablative Conditioning (MAC) Regimen and alloSCT in Children With High-Risk CD33+ AML: A New Targeted Immunochemotherapy Conditioning Regimen (GO-BU/CY)

著录项

引文网络

相似文献

相关主题

期刊订阅